ROCKVILLE, Md.--(BUSINESS WIRE)--Rexahn Pharmaceuticals, Inc. (OTC BB:RXHN), a biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative treatments for cancer, central nervous system disorders, sexual dysfunction and other unmet medical needs, today announced that a U.S. Patent has been granted for the treatment of sexual dysfunction with its leading drug candidate RX-10100 IR, also known as Zoraxel™.
